GW Pharmaceuticals’ Epidiolex Study for Treatment of Childhood Epilepsy Published

GW Pharmaceuticals (GWPH) a London UK-based biopharma company developing CBD therapies, announced that The Lancet, a leading health research journal, published results from its Phase 3 study of CBD-based Epidiolex in patients with Lennox-Gastaut syndrome epilepsy(LGS). In the study, Epidiolex reduced monthly seizure frequency in treatment-resistant patients when added to existing treatment.

Epidiolex is the potential first in a new category of anti-epileptic drugs (AEDs). It is based from cannabidiol (CBD), a cannabinoid without psychoactive effects. If approved, Epidiolex is expected to be available by prescription in the second half of 2018.

GW is a $3.8 billion (market cap) company with revenue of US$11 million in the previous year. It has no positive profit yet, but trades at roughly $138, over 300 times its revenue.

LGS is a rare, lifelong form of epilepsy that begins in childhood and is associated with high mortality and developmental delays. LGS patients suffer from severe seizures which cause falls and injuries. This is the only well-controlled clinical evaluation of a CBD medication for this condition.

GW has submitted a New Drug Application to the FDA for the treatment of LGS and Dravet syndrome. It currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms.

GW commercialized the world’s first plant-derived CBD prescription drug, Sativex (nabiximols), approved for the treatment of spasticity due to multiple sclerosis in many countries outside the US. GW has a pipeline of CBD product candidates including compounds in Phase 1 and 2 trials for glioblastoma, schizophrenia and epilepsy.

GW Pharmaceuticals’ Epidiolex Study for Treatment of Childhood Epilepsy Published

About Cannin Investment Group: Your Pot Stocks Experts

Cannin is your trusted resource for pot stocks. Our global team of experts evaluates all emerging pot stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best pot stock investments for 2020.

Use Cannin as your resource for:

Is it too late to invest in pot stocks? No! This is the perfect time to invest.

Market analysts expect the legal cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in pot stocks is now. Are you looking to buy stock in pot companies for 2020? Interested in emerging penny pot stocks? Looking for the best Canadian pot stocks to invest in? We can help.

Are you interested in pot stocks like Curaleaf, Trulieve, Aurora Cannabis, or Canopy Growth?

Predict price movements of pot stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
108% Backtested since 2012

We’re so confident you’ll love our algotrading pot stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best pot stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks to Invest In

GW Pharmaceuticals’ Epidiolex Study for Treatment of Childhood Epilepsy Published